Nombre del producto: Goserelin
Sinónimos: SAL DE ACETATO DE GOSERELINA;(D-SER(TBU)6,AZAGLY10)-SAL DE ACETATO DE HORMONA LIBERADORA DE GONADOTROPINA;(D-SER(TBU)6,AZAGLY10)-SAL DE ACETATO DE LHRH;(D-SER(TBU)6,AZAGLY10)-SAL DE ACETATO DEL FACTOR LIBERADOR DE HORMONAS LUTEINIZANTES;(D-SER(TBU)6,AZAGLY10)-SAL DE ACETATO DE HORMONA LIBERADORA DE HORMONA LUTEINIZANTE;PYR-SU-TRP-SER-TYR-D-SER(TBU)-SAL DE ACETATO DE LEU-ARG-PRO-AZAGLY-NH2;2-(aminocarbonilo)hidrazida;decapeptidei
CAS: 65807-02-5
MF: C61H88N18O16
megavatio: 1329.46
Goserelin is an analog of luteinizing hormone-releasing hormone (LHRH) useful in the treatment of malignancies responsive to hormonal manipulation. Administered parenterally in a biodegradable depot, goserelin is reportedly as effective as orchidectomy and oophorectomy in patients with advanced prostate carcinoma and pre-menopausal breast cancer.
1. Gonadorelina es otro nombre de la hormona liberadora de gonadotropina. (GnRH). Es un decapéptido sintético preparado mediante síntesis de péptidos en fase sólida.. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary.
2. La GnRH está disponible como clorhidrato de gonadorelina. )y diacetato de gonadorelina tetrahidrato para uso inyectable. Studies have described it being used via an infusion pump system to induce ovulation in patients with hypothalamic hypogonadism. También se utiliza en medicina veterinaria como tratamiento para el ganado con enfermedad quística de ovario..
3. Gonadorelin is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens.
Hombres
Palliative treatment of advanced carcinoma of the prostate; in combination with flutamide for management of locally confined stage T2b to T4 (stage B2 to C) carcinoma of the prostate.
Mujer (3.6 mg only)
Palliative treatment of advanced breast cancer in pre- and perimenopausal women; treatment of endometriosis; as an endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.
